Menu

Eli Lilly hikes sales outlook, as CEO says there's room for 'dramatic' obesity market expansion
📰

Eli Lilly hikes sales outlook, as CEO says there's room for 'dramatic' obesity market expansion

US Top News and Analysis·21 days ago
#rHsYxpFt
#cnbc#business#lilly#quarter#billion
Reading 0:00
15s threshold

Eli Lilly on Thursday reported third-quarter earnings and revenue that blew past estimates and hiked its full-year sales outlook, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soared again.

Despite that strength, sales of its new GLP-1 obesity pill Foundayo, which launched in the U.S. in April, were under Wall Street's expectations for the quarter.

The pharmaceutical giant now expects 2026 revenue to come in between $91 billion and $92 billion, up from a previous guidance of $85 billion to $87 billion.

Lilly projects its full-year adjusted earnings will be between $35 and $36 per share, which compares with a previous outlook of $35.50 to $36.50 per share.…

Continue reading — create a free account

Join HashtagPLUS to read full articles, follow hashtags, vote, and join the conversation.